Personalized medical treatment strategies for patients with chronic myeloid leukemia

References

• Silver R, Woolf S, Hehlmann R et al. An evidence-based analysis of the effect of busulfan, hydroxyurea, interferon, and allogeneic bone marrow transplantation in treating the chronic phase of chronic myeloid leukemia: developed for the American Society of Hematology. Blood 94, 1517–1536 (1999).
   PubMed Web of Science ®Google Scholar
• Hehlmann R, Heimpel H, Hasford J et al. Randomized comparison of interferon-α with busulfan and hydroxyurea in chronic myelogenous leukemia. The German CML Study Group. Blood 84, 4064–4077 (1994).
   PubMed Web of Science ®Google Scholar
• Ohnishi K, Ohno R, Tomonaga M et al. A randomized trial comparing interferon-α with busulfan for newly diagnosed chronic myelogenous leukemia in chronic phase. Blood 86, 906–916 (1995).
   PubMed Web of Science ®Google Scholar
• Allan N, Richards S, Shepherd P et al. UK Medical Research Council randomised, multicentre trial of interferon-αn1 for chronic myeloid leukaemia: improved survival irrespective of cytogenetic response. The UK Medical Research Council’s Working Parties for Therapeutic Trials in Adult Leukaemia. Lancet 345, 1392–1397 (1995).
   PubMed Web of Science ®Google Scholar
• Chronic Myeloid Leukaemia Trialists’Collaborative Group. Interferon α versus chemotherapy for chronic myeloid leukaemia: a meta-analysis of seven randomized trials. J. Natl Cancer Inst. 89, 1616–1620 (1997).
   PubMedGoogle Scholar
• Kantarjian H, Smith T, O’Brien S et al. Prolonged survival in chronic myelogenous leukemia after cytogenetic response to interferon-α therapy. The Leukemia Service. Ann. Intern. Med. 122, 254–261 (1995).
   PubMed Web of Science ®Google Scholar
• Sokal J, Cox E, Baccarani M et al. Prognostic discrimination in ‘good risk’ chronic granulocytic leukaemia. Blood 63, 789–799 (1984).
   PubMed Web of Science ®Google Scholar
• Hasford J, Pfirrmann J, Hehlmann R et al. A new prognostic core for survival of patients with chronic myeloid leukaemia treated with interferon α. J. Natl Cancer Inst. 90, 850–858 (1998).
   PubMed Web of Science ®Google Scholar
• Bonifazi F, de Vivo A, Rosti G et al. Chronic myeloid leukaemia and interferon-α: a study of complete cytogenetic responders. Blood 98, 3074–3081 (2001).
   PubMed Web of Science ®Google Scholar
• Fefer A, Cheever M, Greenberg P et al. Treatment of chronic granulocytic leukaemia with chemoradiotherapy and transplantation of marrow from identical twins. N. Engl. J. Med. 306, 63–68 (1982).
   PubMed Web of Science ®Google Scholar
• Goldman J, Gordon-Smith E, Catovsky D, Galton D, Reid C. Timing of transplant for CML patients. Blood 64, 945–946 (1984).
   PubMed Web of Science ®Google Scholar
• Peggs K, MacKinnon S. Imatinib mesylate – the new gold standard for treatment of chronic myeloid leukaemia. N. Engl. J. Med. 348, 1048–1050 (2003).
   PubMed Web of Science ®Google Scholar
• Clift R, Storb R. Marrow transplantation for CML: the Seattle experience. Bone Marrow Transplant. 17(Suppl. 3), S1–S3 (1996).
   Web of Science ®Google Scholar
• Horowitz M, Rowlings P, Passweg J et al. Allogeneic bone marrow transplantation for CML: a report from the International Bone Marrow Transplant Registry. Bone Marrow Transplant. 17(Suppl. 3), S5–S6 (1996).
   Google Scholar
• van Rhee F, Szydlo R, Hermans J et al. Long-term results after allogeneic bone marrow transplantation for chronic myelogenous leukemia in chronic phase: a report from the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant. 20, 553–560 (1997).
   PubMed Web of Science ®Google Scholar
• Champlin R, Schmitz N, Horowitz M et al. Blood stem cells compared with bone marrow as a source of hematopoietic cells for allogeneic transplantation. Blood 95, 3702–3709 (2000).
   PubMed Web of Science ®Google Scholar
• Giralt S, Szydlo R, Goldman J et al. Effect of short-term interferon therapy on the outcome of subsequent HLA-identical sibling bone marrow transplantation for chronic myelogenous leukemia. Blood 95, 410–415 (2000).
   PubMed Web of Science ®Google Scholar
• Ohnishi K, Ino T, Kishimoto Y et al. Multicenter prospective study of interferon-α versus bone marrow transplantation for newly diagnosed patients with chronic myelogenous leukemia: a preliminary analysis. Cancer Chemother. Pharmacol. 48(Suppl. 1), S59–S64 (2001).
   Google Scholar
• Gaziev D, Galimberti M, Polchi P et al. Fate of chronic myeloid leukemia patients treated with allogeneic bone marrow transplantation or chemotherapy and/or interferon at a single center: long-term results. Bone Marrow Transplant. 29, 1–8 (2002).
   PubMed Web of Science ®Google Scholar
• Weisdorf DJ, Anasetti C, Antin J et al. Allogeneic bone marrow transplantation for chronic myelogenous leukemia: comparative analysis of unrelated versus matched sibling donor transplantation. Blood 99, 1971–1977 (2002).
   PubMed Web of Science ®Google Scholar
• Cwynarski K, Roberts I, Iacobelli S et al. Stem cell transplantation for chronic myeloid leukemia in children. Blood 102, 1224–1231 (2003).
   PubMed Web of Science ®Google Scholar
• Hansen J, Gooley T, Martin P et al. Bone marrow transplants from unrelated donors for patients with chronic myeloid leukemia. N. Engl. J. Med. 338, 962–968 (1998).
   PubMed Web of Science ®Google Scholar
• Kolb H, Mittermuller J, Clemm C et al. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood 76, 2462–2465 (1990).
   PubMed Web of Science ®Google Scholar
• Kolb H, Schattenberg A, Goldman J et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. European Group for Blood and Marrow Transplantation Working Party Chronic Leukemia. Blood 86, 2041–2050 (1995).
   PubMed Web of Science ®Google Scholar
• Slavin S, Naparstek E, Nagler A, Ackerstein A, Kapelushnik Y, Or R. Allogeneic cell therapy for relapsed leukemia after bone marrow transplantation with donor peripheral blood lymphocytes. Exp. Hematol. 23, 1553–1562 (1995).
   PubMed Web of Science ®Google Scholar
• Slavin S, Naparstek E, Nagler A, Kapelushnik Y, Ackerstein A, Or R. Allogeneic cell therapy: the treatment of choice for all hematologic malignancies relapsing post BMT. Blood 87, 4011–4013 (1996).
   PubMed Web of Science ®Google Scholar
• Gratwohl A, Hertmans J, Goldman J et al. Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation. Lancet 352, 1087–1092 (1998).
   PubMed Web of Science ®Google Scholar
• Passweg J, Walker I, Sobocinski K et al. Chronic Leukemia Study Writing Committee of the International Bone Marrow Transplant Registry. Validation and extension of the EBMT Risk Score for patients with chronic myeloid leukaemia (CML) receiving allogeneic haematopoietic stem cell transplants. Br. J. Haematol. 125, 613–620 (2004).
   PubMed Web of Science ®Google Scholar
• Or R, Shapira MY, Resnick I et al. Nonmyeloablative allogeneic stem cell transplantation for the treatment of chronic myeloid leukemia in first chronic phase. Blood 101, 441–445 (2003).
   PubMed Web of Science ®Google Scholar
• Doubek M, Vitek A, Mayer J. Reduced-intensity allografting for chronic myeloid leukaemia in the first chronic phase. Haematologica 89, elt03 (2004).
   PubMedGoogle Scholar
• Gilleece M, Dazzi F. Donor lymphocyte infusions for patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukaemia. Leuk. Lymphoma 44, 23–28 (2003).
   PubMed Web of Science ®Google Scholar
• Marks D, Lush R, Cavenagh J et al. The toxicity and efficacy of donor lymphocyte infusions given after reduced-intensity conditioning allogeneic stem cell transplantation. Blood 100, 3108–3114 (2002).
   PubMed Web of Science ®Google Scholar
• Crawley C, Lalancette M, Szydlo R et al. Reduced intensity conditioned allografts for chronic myeloid leukaemia: a study from the Chronic Leukaemia Working Party of the EBMT. Blood 100, 3089a (2002).
   Google Scholar
• Weisser M, Schleuning M, Ledderose G et al. Reduced-intensity conditioning using TBI (8 Gy), fludarabine, cyclophosphamide and ATG in elderly CML patients provides excellent results especially when performed in the early course of the disease. Bone Marrow Transplant. 34, 1083–1088 (2004).
   PubMed Web of Science ®Google Scholar
• Druker B, Tamura S, Buchdunger E et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr–Abl positive cells. Nature Med. 2, 561–566 (1996).
   PubMed Web of Science ®Google Scholar
• Druker B, Lydon N. Lessons learned from the development of an Abl tyrosine kinase inhibitor for chronic myelogenous leukaemia. J. Clin. Invest. 105, 3–7 (2000).
   PubMed Web of Science ®Google Scholar
• Druker B, Talpaz M, Resta D et al. Efficacy and safety of a specific inhibitor of the Bcr–Abl tyrosine kinase in chronic meyloid leukemia. N. Engl. J. Med. 344, 1031–1037 (2001).
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Sawyers C, Hochhaus A et al. International STI571 CML Study Group. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N. Engl. J. Med. 346, 645–652 (2002).
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Cortes J, O’Brien S et al. Long-term survival benefit and improved complete cytogenetic and molecular response rates with imatinib mesylate in Philadelphia chromosome-positive, chronic-phase chronic myeloid leukemia after failure of interferon-α. Blood 104, 1979–1988 (2004).
   PubMed Web of Science ®Google Scholar
• Talpaz M, Silver R, Druker B et al. Imatinib induces durable hematologic and cytogentic responses in patients with accelerated phase chronic myeloid leukemia: results of a Phase II study. Blood 99, 1928–1937 (2002).
   PubMed Web of Science ®Google Scholar
• Sawyers C, Hochhaus A, Feldman E et al. Imatinib induces hematologic and cytogentic response in patients with chronic myelogenous leukaemia in myeloid blast crisis: results of a Phase II study. Blood 99, 3530–3539 (2002).
   PubMed Web of Science ®Google Scholar
• Wadhwa J, Szydlo R, Apperley J et al. Factors affecting duration of survival after onset of blastic transformation of chronic myeloid leukemia. Blood 99, 2304–2309 (2002).
   PubMed Web of Science ®Google Scholar
• O’Brien S, Guilhot F, Larson R et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N. Engl. J. Med. 348, 994–1004 (2003).
   PubMed Web of Science ®Google Scholar
• Guilhot F. Sustained durability of responses plus high rates of cytogenetic responses result in long-term benefit for newly diagnosed chronic-phase chronic myeloid leukemia (CML-CP) treated with imatinib (IM) therapy: update from the IRIS study. Blood 104, 21a (2004).
   Google Scholar
• Kantarjian H, Talpaz M, O’Brien S et al. Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemia. Blood 101, 473–475 (2003).
   PubMed Web of Science ®Google Scholar
• Cortes J, Giles F, O’Brien S et al. Result of high-dose imatinib mesylate in patients with Philadelphia chromosome-positive chronic myeloid leukemia after failure of interferon-α. Blood 102, 83–86 (2003).
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Talpaz M, O’Brien S et al. High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukaemia. Blood 103, 2873–2878 (2004).
   PubMed Web of Science ®Google Scholar
• Mahon F, Delbrel X, Cony-Makhoul P et al. Follow-up of complete cytogenetic remission in patients with chronic myeloid leukemia after cessation of interferon α. J. Clin. Oncol. 20, 214–220 (2002).
   PubMed Web of Science ®Google Scholar
• Branford S, Hughes T, Rudzki Z. Monitoring chronic myeloid leukaemia therapy by real-time quantitative PCR in blood is a reliable alternative to bone marrow cytogenetics. Br. J. Haematol. 107, 587–599 (1999).
   PubMed Web of Science ®Google Scholar
• Olavarria E, Kanfer E, Szydlo R et al. Early detection of Bcr–Abl transcripts by quantitative reverse transcriptase-polymerase chain reaction predicts outcome after allogeneic stem cell transplantation for chronic myeloid leukemia. Blood 97, 1560–1565 (2001).
   PubMed Web of Science ®Google Scholar
• Radich J, Gooley T, Bryant E et al. The significance of Bcr–Abl molecular detection in chronic myeloid leukemia patients ‘late,’ 18 months or more after transplantation. Blood 98, 1701–1707 (2001).
   PubMed Web of Science ®Google Scholar
• Merx K, Muller MC, Kreil S et al. Early reduction of Bcr–Abl mRNA transcript levels predicts cytogenetic response in chronic phase CML patients treated with imatinib after failure of interferon α. Leukemia 16, 1579–1583 (2002).
   PubMed Web of Science ®Google Scholar
• Hughes T, Kaeda J, Branford S et al. Frequency of major molecular responses to imatininb or interferon α plus cytarabine in newly diagnosed chronic myeloid leukaemia. N. Engl. J. Med. 349, 1421–1430 (2003).
   Web of Science ®Google Scholar
• Wang L, Pearson K, Ferguson J, Clark R. The early molecular response to imatinib predicts cytogenetic and clinical outcome in chronic myeloid leukaemia. Br. J. Haematol. 120, 990–999 (2003).
   PubMed Web of Science ®Google Scholar
• Branford S, Rudzki Z, Walsh S et al. Detection of Bcr–Abl mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis. Blood 102, 276–283 (2003).
   PubMed Web of Science ®Google Scholar
• Hochhaus A, Reiter A, Saussele S et al. Molecular heterogeneity in complete cytogenetic responders after interferon-α therapy for chronic myelogenous leukemia: low levels of minimal residual disease are associated with continuing remission. Blood 95, 62–66 (2000).
   PubMed Web of Science ®Google Scholar
• Kurzrock R, Estrov Z, Kantarjian H, Talpaz M. Conversion of interferon-induced, long-term cytogenetic remissions in chronic myelogenous leukemia to polymerase chain reaction negativity. J. Clin. Oncol.16, 1526–1531 (1998).
   PubMed Web of Science ®Google Scholar
• Paschka P, Muller M, Merx K et al. Molecular monitoring of response to imatinib (Glivec) in CML patients pretreated with interferon α. Low levels of residual disease are associated with continuous remission. Leukemia 17, 1687–1694 (2003).
   PubMed Web of Science ®Google Scholar
• Gorre M, Mohammed M, Ellwood K et al. Clinical resistance to STI-571 cancer therapy caused by Bcr–Abl gene mutation or amplification. Science 293, 876–880 (2001).
   PubMed Web of Science ®Google Scholar
• Branford S, Rudzki Z, Walsh S et al. High frequency of point mutations clustered within the adenosine-triphosphate-binding region of Bcr/Abl in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance. Blood 99, 3472–3475 (2002).
   PubMed Web of Science ®Google Scholar
• Hochhaus A, Kreil S, Corbin A et al. Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Leukemia 16, 2190–2196 (2002).
   PubMed Web of Science ®Google Scholar
• Shah N, Nicoll J, Nagar B et al. Multiple Bcr–Abl kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis CML. Cancer Cell 2, 117–125 (2002).
   PubMed Web of Science ®Google Scholar
• von Bubnoff N, Schneller F, Peschel C et al. Bcr–Abl gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI571: a prospective study. Lancet 359, 487–491 (2002).
   PubMed Web of Science ®Google Scholar
• Corbin A, Buchdunger E, Pascal F, Druker B. Analysis of the structural basis of specificity of inhibition of the Abl kinase by STI571. J. Biol. Chem. 277, 32214–32219 (2002).
   PubMed Web of Science ®Google Scholar
• Corbin A, La Rosee P, Stoffregen E et al. Several Bcr–Abl kinase domain mutants associated with imatinib mesylate resistance remain sensitive to imatinib. Blood 101, 4611–4614 (2003).
   PubMed Web of Science ®Google Scholar
• Branford S, Rudzki Z, Parkinson I et al. Real-time quantitative PCR analysis can be used as a primary screen to identify imatinib-treated patients with CML who have Bcr–Abl kinase domain mutations. Blood 104, 2926–2932 (2004).
   PubMed Web of Science ®Google Scholar
• Carella A. Autotransplants in chronic myeloid leukaemia. Oncologist 3, 54–60 (1998).
   PubMedGoogle Scholar
• O’Dwyer M, Mauro M, Kuyl J, Paquette R, Sawyers C, Druker B. Preliminary evaluation of the combination of imatinib mesylate (Gleevec) in combination with low dose interferon-α for the treatment of chronic phase CML. Blood 100, 846a (2001).
   Google Scholar
• O’Brien S, Kantarjian H, Keating M et al. Homoharringtonine therapy induces responses in patients with chronic myelogenous leukemia in late chronic phase. Blood 86, 3322–3326 (1995).
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Talpaz M, Smith T et al. Homoharringtonine and low-dose cytarabine in the management of late chronic-phase chronic myelogenous leukemia. J. Clin. Oncol. 18, 3513–3521 (2000).
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Talpaz M, Santini V et al. Homoharringtonine: history, current research, and future direction. Cancer 92, 1591–1605 (2001).
   PubMed Web of Science ®Google Scholar
• Kantarjian H, O’Brien S, Cortes J et al. Results of decitabine (5-aza-2´deoxycytidine) therapy in 130 patients with chronic myelogenous leukemia. Cancer 98, 522–528 (2003).
   PubMed Web of Science ®Google Scholar
• Li Z, Qiao Y, Laska E et al. Autologous leukocyte-derived heat shock protein 70–peptide complex as a vaccine for chronic myelogenous leukemia in chronic phase: an updated Phase I study. Blood 102, 3392a (2003).
   Google Scholar
• Cortes J, Albitar M, Thomas D et al. Efficacy of the farnesyl transferase inhibitor R115777 in chronic myeloid leukemia and other hematological malignancies Blood 101, 1692–1697 (2003).
   PubMed Web of Science ®Google Scholar
• Shah N, Tran C, Lee F, Chen P, Norris D, Sawyers C. Overriding imatinib resistance with a novel Abl kinase inhibitor. Science 305, 399–401 (2004).
   PubMed Web of Science ®Google Scholar
• O’Hare T, Pollock R, Stoffregen et al. Inhibition of wild type and mutant Bcr–Abl by AP23464, a potent ATP-based oncogenic protein kinase inhibitor: implications for CML. Blood 104, 2532–2539 (2004).
   PubMed Web of Science ®Google Scholar